Should I buy or sell Legend Biotech stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares. View LEGN analyst ratings or view top-rated stocks .

What is Legend Biotech's stock price target for 2024?

14 equities research analysts have issued 1 year price objectives for Legend Biotech's stock. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's stock price to reach $82.70 in the next twelve months. This suggests a possible upside of 59.9% from the stock's current price. View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts .

How have LEGN shares performed in 2024?

Legend Biotech's stock was trading at $60.17 at the beginning of 2024. Since then, LEGN shares have decreased by 14.1% and is now trading at $51.71. View the best growth stocks for 2024 here .

When is Legend Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our LEGN earnings forecast .

How can I listen to Legend Biotech's earnings call?

Legend Biotech will be holding an earnings conference call on Monday, May 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Legend Biotech's earnings last quarter?

Legend Biotech Co. (NASDAQ:LEGN) announced its earnings results on Monday, March, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.30. The firm earned $76.50 million during the quarter, compared to the consensus estimate of $95.63 million. Legend Biotech had a negative trailing twelve-month return on equity of 37.19% and a negative net margin of 181.75%. The business's quarterly revenue was up 177.2% on a year-over-year basis.

What ETFs hold Legend Biotech's stock?

ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Harbor Health Care ETF (MEDI) , Global X MSCI China Health Care ETF (CHIH) , Loncar China Biopharma ETF (CHNA) , Fidelity Disruptive Medicine ETF (FMED) , KraneShares MSCI All China Health Care Index ETF (KURE) , Virtus LifeSci Biotech Products ETF (BBP) , BlackRock Future Health ETF (BMED) and Range Cancer Therapeutics ETF (CNCR) .

What other stocks do shareholders of Legend Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD) , NVIDIA (NVDA) , CrowdStrike (CRWD) , Lam Research (LRCX) , ServiceNow (NOW) , Peloton Interactive (PTON) , QUALCOMM (QCOM) , Applied Materials (AMAT) , DocuSign (DOCU) and Etsy (ETSY) .

When did Legend Biotech IPO?

Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.

Who are Legend Biotech's major shareholders?

Legend Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Matthews International Capital Management LLC (0.41%).

How do I buy shares of Legend Biotech?

Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:LEGN

Legend Biotech (LEGN) Stock Price, News & Analysis

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)

Free LEGN Stock Alerts

$49.92

-1.79 (-3.46%)

(As of 09:46 AM ET)

Compare

Today's Range: $49.13
▼
$50.58
50-Day Range: $51.71
▼
$69.99
52-Week Range: $49.13
▼
$77.32

Volume: 307,017 shs
Average Volume: 953,131 shs
Market Capitalization: $9.08 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $82.70

Get Legend Biotech alerts:

Legend Biotech MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 59.9% Upside
$82.70 Price Target
Short Interest: Bearish
5.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.03
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.42) to $0.08 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.28 out of 5 stars

Medical Sector

535th out of 928 stocks

Pharmaceutical Preparations Industry

248th out of 432 stocks

4.4

Analyst's Opinion

Consensus Rating
Legend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Legend Biotech has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.49% of the outstanding shares of Legend Biotech have been sold short.
Short Interest Ratio / Days to Cover
Legend Biotech has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.
Change versus previous month
Short interest in Legend Biotech has recently decreased by 4.95%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Legend Biotech does not currently pay a dividend.
Dividend Growth
Legend Biotech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LEGN.

1.7

News and Social Media Coverage

News Sentiment
Legend Biotech has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Legend Biotech this week, compared to 4 articles on an average week.
Search Interest
Only 4 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Legend Biotech insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.02% of the stock of Legend Biotech is held by insiders.
Percentage Held by Institutions
70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Legend Biotech are expected to grow in the coming year, from ($1.42) to $0.08 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Legend Biotech is -34.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Legend Biotech is -34.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Legend Biotech has a P/B Ratio of 7.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

A.I. “Perfect Storm” Could Send THESE Stocks Sky High

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

About Legend Biotech Stock (NASDAQ:LEGN)

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

LEGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LEGN Stock News Headlines

April 14, 2024 | nasdaq.com

LEGN Quantitative Stock Analysis

April 14, 2024 | nasdaq.com

Legend Biotech is Now Oversold (LEGN)

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

April 11, 2024 | businesswire.com

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

April 11, 2024 | americanbankingnews.com

Q2 2024 EPS Estimates for Legend Biotech Co. Decreased by HC Wainwright (NASDAQ:LEGN)

April 10, 2024 | americanbankingnews.com

Q1 2024 Earnings Estimate for Legend Biotech Co. (NASDAQ:LEGN) Issued By HC Wainwright

April 9, 2024 | americanbankingnews.com

Legend Biotech Co. (NASDAQ:LEGN) Receives Average Recommendation of "Moderate Buy" from Brokerages

April 9, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

April 7, 2024 | markets.businessinsider.com

Buy Rating on Legend Biotech: FDA Approval and Market Potential Bolster Carvykti’s Outlook

April 6, 2024 | finance.yahoo.com

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

April 5, 2024 | businesswire.com

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

April 3, 2024 | finance.yahoo.com

Should You Continue to Hold Legend Biotech Corporation (LEGN)?

April 2, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Shockwave Medical (SWAV), Veeva Systems (VEEV)

April 1, 2024 | seekingalpha.com

Natera and Alliance for Clinical Trials in Oncology announce activation of mid-stage trial in urothelial cancer

March 31, 2024 | msn.com

Stock market bubble warnings are everywhere. These are the 10 most richly valued stocks right now.

March 29, 2024 | finance.yahoo.com

Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4

March 24, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Legend Biotech (LEGN)

March 20, 2024 | benzinga.com

GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy

March 19, 2024 | finance.yahoo.com

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

March 16, 2024 | nasdaq.com

Guru Fundamental Report for LEGN

March 15, 2024 | msn.com

Johnson & Johnson wins FDA AdCom backing for Carvykti label expansion

March 15, 2024 | businesswire.com

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

March 15, 2024 | seekingalpha.com

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

March 12, 2024 | msn.com

Company News for Mar 12, 2024

March 12, 2024 | finance.yahoo.com

Legend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call Transcript

March 11, 2024 | seekingalpha.com

Legend Biotech Corporation 2023 Q4 - Results - Earnings Call Presentation

See More Headlines

Receive LEGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/16/2024
Next Earnings (Confirmed): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LEGN
CUSIP: N/A
CIK: 1801198
Web: www.legendbiotech.com
Phone: 732-317-5050
Fax: N/A
Employees: 1,800
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $82.70
High Stock Price Target: $94.00
Low Stock Price Target: $64.00
Potential Upside/Downside: +65.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-518,250,000.00
Net Margins: -181.75%
Pretax Margin: -182.41%
Return on Equity: -37.19%
Return on Assets: -25.34%

Debt

Debt-to-Equity Ratio: 0.22
Current Ratio: 6.92
Quick Ratio: 6.83

Sales & Book Value

Annual Sales: $285.14 million
Price / Sales: 31.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.88 per share
Price / Book: 7.26

Miscellaneous

Outstanding Shares: 181,910,000
Free Float: 181,875,000
Market Cap: $9.08 billion
Optionable: Optionable
Beta: 0.01

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Ying Huang Ph.D. (Age 51)
CEO & Director
Mr. Doug Wallace
Vice President of Global Operations
Dr. Guowei Fang Ph.D.
Chief Scientific Officer & Head of Business Development
Joanne Choi
Senior Manager of Investor Relations
Mr. James Pepin J.D.
General Counsel
Deborah Wong
Executive Director of Strategic Marketing & Corporate Communications
Ms. Elaine Qian
VP & Global Head of Human Resources
Dr. Yuhong Qiu Ph.D.
Senior Vice President of Global Regulatory Affairs
Mr. Steven J. Gavel
Senior Vice President of Commercial Development, US & Europe
Mr. Alan Kick
Senior Vice President of Global Quality

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LEGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Legend Biotech stock right now?: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Legend Biotech in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LEGN shares.
View LEGN analyst ratings or view top-rated stocks.
What is Legend Biotech's stock price target for 2024?: 14 equities research analysts have issued 1 year price objectives for Legend Biotech's stock. Their LEGN share price targets range from $64.00 to $94.00. On average, they expect the company's stock price to reach $82.70 in the next twelve months. This suggests a possible upside of 59.9% from the stock's current price.
View analysts price targets for LEGN or view top-rated stocks among Wall Street analysts.
How have LEGN shares performed in 2024?: Legend Biotech's stock was trading at $60.17 at the beginning of 2024. Since then, LEGN shares have decreased by 14.1% and is now trading at $51.71.
View the best growth stocks for 2024 here.
When is Legend Biotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our LEGN earnings forecast.
How can I listen to Legend Biotech's earnings call?: Legend Biotech will be holding an earnings conference call on Monday, May 13th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Legend Biotech's earnings last quarter?: Legend Biotech Co. (NASDAQ:LEGN) announced its earnings results on Monday, March, 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.30. The firm earned $76.50 million during the quarter, compared to the consensus estimate of $95.63 million. Legend Biotech had a negative trailing twelve-month return on equity of 37.19% and a negative net margin of 181.75%. The business's quarterly revenue was up 177.2% on a year-over-year basis.

What ETFs hold Legend Biotech's stock?: ETFs with the largest weight of Legend Biotech (NASDAQ:LEGN) stock in their portfolio include Harbor Health Care ETF (MEDI), Global X MSCI China Health Care ETF (CHIH), Loncar China Biopharma ETF (CHNA), Fidelity Disruptive Medicine ETF (FMED), KraneShares MSCI All China Health Care Index ETF (KURE), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Health ETF (BMED) and Range Cancer Therapeutics ETF (CNCR).
What other stocks do shareholders of Legend Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON), QUALCOMM (QCOM), Applied Materials (AMAT), DocuSign (DOCU) and Etsy (ETSY).
When did Legend Biotech IPO?: Legend Biotech (LEGN) raised $350 million in an initial public offering on Friday, June 5th 2020. The company issued 18,400,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO.
Who are Legend Biotech's major shareholders?: Legend Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Matthews International Capital Management LLC (0.41%).
How do I buy shares of Legend Biotech?: Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LEGN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial